Lillie James Woodruff 4

What Happened

• Lillie James Woodruff, Chief Scientific Officer of MapLight Therapeutics (MPLT), sold a total of 4,513 shares in open-market/private sales on April 15–16, 2026 for aggregate proceeds of approximately $122,575. Breakdown: 1,730 shares @ $26.82 (Apr 15) = $46,399; 686 shares @ $27.01 (Apr 16) = $18,529; 2,097 shares @ $27.49 (Apr 16) = $57,647. These transactions are reported as sales (S) and per the filing some shares were sold to cover statutory tax withholding related to RSU vesting.

Key Details

• Transaction dates and prices:
  • 2026-04-15: 1,730 shares @ $26.82 = $46,399
  • 2026-04-16: 686 shares @ $27.01 = $18,529
  • 2026-04-16: 2,097 shares @ $27.49 = $57,647
• Total sold: 4,513 shares for ~$122,575.
• Footnotes: filing notes that some shares were sold to cover tax withholding on vested RSUs (F1). Reported prices are weighted averages with sales occurring across price ranges (see footnotes F2, F4, F5). The filing also notes 808 shares were acquired under the company’s employee stock purchase plan on March 31, 2026 (F3).
• Shares owned after the transactions: not specified in the provided excerpt.
• Filing timeliness: Report is dated Apr 17, 2026 for transactions through Apr 15–16, 2026 — the filing appears to have been made promptly.

Context

• These were outright sales (S) rather than purchases or option exercises. Sales to cover tax withholding for RSU vesting are common and typically routine (not necessarily a directional signal about insider view). No options exercised or gifts were reported in the provided transactions.